Referring Clinicians
Trials Recruiting at ACTC
| Tumour Stream | Trial Name | Study Description | Key Investigational Agent | Key Inclusion Criteria | Recruitment Status |
|---|---|---|---|---|---|
| Multiple tumour stream | GILEAD (GS-US-494-5484) | A Phase 1b/2 Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in Subjects with Advanced Solid Tumors | GS-4224 (small molecule oral PDL1 Inhibitor) | Advanced Solid Organ Malignancy with no further treatment options. TPS/CPS >10% on pre-screening of archival tissue | Biopsy sub-study Recruiting |
| Melanoma (Advanced/ Metastatic) | MK1308-001 | A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors | MK1308 (CTLA4 Inhibitor) +/- Pembrolizumab (6 weekly) | Metastatic Melanoma with disease progression after PD1 or PDL1 checkpoint inhibitor therapy | Recruiting |
| Merkel Cell Carcinoma | MK-3475-913 | A phase 1 open label, multi-arm , multicenter study of MK-1308 in combination with pembrolizumab for subjects with advanced solid organ tumours | Pembrolizumab(antiPD1) | Unresectable Stage III and Stage IV Merkel Cell Carcinoma( 1st line) | Recruiting |
| Melanoma, NSCLC | NP40435 | Phase 1b study to evaluate safety, pharmacokinetic and preliminary anti-tumour activity of R07121661, PD-l/TIM3 Bispecific Antibody in patients with advanced and/or metastatic solid tumours | PD1/TIM3 bi-specific antibody | -Melanoma: after PD1+/- CTLA4 inhibitor (includes uveal melanoma) -NSCLC: CPI experienced, post platinum, must have received at least 4 months of CPI, PDL1>1% | Recruiting |
| Cervical SCC | BP40234 | An Open Label Phase 2 Study Evaluating the activity of FAP-Interleukin2 Variant and Atezolizumab in advanced Solid Organ Cancer | Atezolizumab + FAP Interleukin2 Variant | Second or subsequent line systemic therapy | Recruiting |
How to Refer
Please email all referrals to CentralReferrals@adhb.govt.nz (include Att: ACTC in email subject)
Email us for any other inquiries: infoACTC@adhb.govt.nz
Auckland Cancer Trials Centre
Auckland City Hospital,
2, Park Road, Grafton,
1023, Auckland, New Zealand
Patient Referrals
Please email all referrals to: CentralReferrals@adhb.govt.nz (include Att: ACTC in email subject)